Drug Trial Radar · NCT07569081
A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
136
Planned (sponsor's estimate)
Start
Nov 2, 2026
Primary completion
Dec 19, 2028
Study completion Jun 17, 2031
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of momelotinib in participants with a diagnosis of VEXAS.
Conditions
- VEXAS Syndrome
Interventions
MomelotinibDrug
Momelotinib will be administered
GlucocorticoidsDrug
Glucocorticoids (prednisone or prednisolone) will be administered
PlaceboDrug
Placebo will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR (Objective response rate) at Week 26Time frame: At Week 26
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Salzburg, Austria
GSK Investigational Site
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.